Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Receivables: 2016-2025

Historic Receivables for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $114.6 million.

  • Ultragenyx Pharmaceutical's Receivables rose 20.55% to $114.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $464.8 million, marking a year-over-year increase of 22.84%. This contributed to the annual value of $123.6 million for FY2024, which is 65.93% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Receivables stood at $114.6 million for Q3 2025, which was down 8.55% from $125.4 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Receivables registered a high of $125.4 million during Q2 2025, and its lowest value of $28.5 million during Q2 2021.
  • Its 3-year average for Receivables is $95.6 million, with a median of $100.5 million in 2024.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Receivables slumped by 34.96% in 2021, and later spiked by 131.82% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Receivables (Quarterly) stood at $44.4 million in 2021, then rose by 5.43% to $46.8 million in 2022, then skyrocketed by 59.01% to $74.5 million in 2023, then skyrocketed by 65.93% to $123.6 million in 2024, then climbed by 20.55% to $114.6 million in 2025.
  • Its Receivables was $114.6 million in Q3 2025, compared to $125.4 million in Q2 2025 and $101.2 million in Q1 2025.